Pilot study of administration of psilocybin in healthy volunteers within a marae

Single-group, open-label Phase I feasibility study enrolling 12 healthy Māori volunteers to receive a single 25 mg oral capsule of psilocybin in a marae setting with clinical and cultural supervision.

Primary outcomes are feasibility and acceptability; safety assessed via adverse events, vitals and screening for suicidality (C-SSRS). Key exclusions include personal or first-degree family history of psychosis, recent psychedelic use, substance dependence, and BMI outside 18–35.